This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Greetings and welcome to the NeurogesX, Inc., Second Quarter 2012 Earnings Conference call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (Operator instructions) As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Nicole Greenbaum of the Ruth Group. Thank you, Ms. Greenbaum. You may now begin.
Thank you operator. Joining us on the call today are Ronald Martell, President and Chief Executive Officer; Stephen Ghiglieri, Executive Vice President, Chief Operating Officer and Chief Financial Officer; Michael Markels, Senior Vice President, Commercial and Business Development; and Dr. Stephen J. Peroutka, Executive Vice President and Chief Medical Officer.
Statements in this conference call regarding NeurogesX’s business which are not historical facts may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 or the Act. NeurogesX disclaims any intent or obligation to update these forward-looking statements and claims protection of the Safe Harbor for forward-looking statements contained in the Act.
Forward-looking statements may include, but are not limited to, statements regarding expected quarterly cash usage rates for 2012, expectations and timing with respect to our entering NGX-1998 into Phase 3 clinical trial; the potential timeline of development of NGX-1998; and End-of-Phase 2 meeting with the FDA for NGX-1998 and expected areas of focus and benefits from such meetings and interactions with the FDA, securing and development partner for NGX-1998, the sufficiency of cash to fund operations well into 2013, expected reduced revenues from Qutenza commercialization efforts and expectations respect to such commercialization efforts, the benefits of NGX-1998 including as compared to Qutenza and its potential market advantage, and potential participation of our commercial partner in development of NGX-1998.